



PALLA PHARMA

ASX ANNOUNCEMENT

Monday 10 February 2020

Full Year Results Presentation and Investor Conference Call

Palla Pharma Limited (ASX:PAL) advises that Chief Executive Officer Jarrod Ritchie and Chief Financial Officer Brendan Middleton will host an analyst and investor conference call on Thursday 27 February 2020 at 10.30am AEDT to present the Company's results for the full year ended 31 December 2019.

An accompanying presentation will be made available via the ASX announcement platform prior to the call.

Conference call details

To pre-register for this conference and avoid a queue when calling, please use the following link below:

<https://sl.c-conf.com/diamondpass/10003974-invite.html>

You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

If you are unable to register, then at the time of the conference you can call one of the numbers below and provide the **conference ID 10003974** to an operator:

- Attendee Dial-in (Australia Toll Free): **1 800 558 698**
- Alternate Australia Toll Free: **1 800 809 971**

This announcement has been authorised for release by the Board.

For more information please contact:

Jarrod Ritchie

Chief Executive Officer
Palla Pharma Limited
+61 3 9301 0800

Adrian Mulcahy

Investor Relations
Market Eye
+61 438 630 422 or ir@pallapharma.com

Brendan Middleton

Chief Financial Officer
Palla Pharma Limited
+61 3 9301 0800

Tristan Everett

Media Enquiries
Market Eye
+61 403 789 096 or media@pallapharma.com

About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

T +61 3 9301 0800 / F +61 3 9301 0899 / W pallapharma.com / E info@pallapharma.com